Novartis Zelnorm uptake
Executive Summary
More than 70% of "top-tier" gastrointestinal specialists are prescribing the irritable bowel syndrome agent Zelnorm, Novartis Pharmaceutical CEO Thomas Ebeling tells investors April 15. "Tier one" physicians have on average 16-18 patients on tegaserod, he says. By comparison, second and third tier specialists have six to eight patients on the IBS agent, with roughly 45% and 35% of tier two and three physicians prescribing, respectively. Novartis previously described uptake for the specialist community as a whole, with 25% prescribing Zelnorm (1"The Pink Sheet" Oct. 21, 2002, p. 24)...
You may also be interested in...
Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months
The uptake of Novartis' irritable bowel syndrome therapy Zelnorm will accelerate after physicians obtain more "feedback" from early users, U.S. Commercial Operations General Manager Kurt Graves said Oct. 17 during a Novartis R&D briefing in New York City
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.